Drugs / TP 6076
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03691584 | Nov 2018 → Jun 2019 | — | Tetraphase Pharmaceuticals, Inc | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TP 6076 | “The dose planned to be administered in this study is an iv infusion of 30 mg TP 6076 q24h for 4 consecutive days (starting on Day 1 and ending on Day 4).” NCT03691584 ↗ |
| Modality | Small molecule | — CHEMBL6068527 ↗ |
| Route | Intravenous | “iv infusion” NCT03691584 ↗ |